Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Pan Y, Jin H, Chen W, Yu Z, Ye T, Zheng Y, Weng Z, Wang FAbstract PURPOSE: The aim of this study was to evaluate the efficacy and safety of zoledronic acid (ZA) in the...
Bishop JL, Sio A, Angeles A, Roberts ME, Azad AA, Chi KN, Zoubeidi A.Oncotarget. 2015 Jan 1;6(1):234-42.
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer
Raya Leibowitz-Amit, Arnoud J. Templeton, Shabbir M. Alibhai, Jennifer J. Knox, Srikala S. Sridhar, Ian F. Tannock, Anthony M. Joshua
Journal of Geriatric Oncology, 1, 6, pages 23 - 28
Salvatore L. Burgio, Vincenza Conteduca, Britt Rudnas, Francesco Carrozza, Enrico Campadelli, Emanuela Bianchi, Paolo Fabbri, Marco Montanari, Elisa Carretta, Cecilia Menna, Ugo De Giorgi
Clinical Genitourinary Cancer
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer
Prof Charles J Ryan, MD, Prof Matthew R Smith, MD, Prof Karim Fizazi, MD, et al.The Lancet Oncology, Volume 16, No. 2, p152–160, February 2015
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Vice Chairman of the Department of Urologic Oncology, as well as Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.
- Apr 201527Apr 201528Contact: Ms. Sabine Weinberger, Ms. Miriam Faik Tel.: +43 (0)50 504 36310 Fax: +43 (0)50 504 67 36310 E-mail: LKH.firstname.lastname@example.org
- May 201529Jun 20152Contact: ASCO Tel.: +1 571 483 1300 E-mail: email@example.com